MEDI 0382

Drug Profile

MEDI 0382

Alternative Names: MEDI0382

Latest Information Update: 27 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Class Antihyperglycaemics; Obesity therapies; Peptides
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 25 Jul 2018 MedImmune plans a phase IIa trial for Type-2 diabetes mellitus and Obesity (In adults, In the elderly) in United Kingdom (NCT03596177)
  • 29 Jun 2018 Phase-II clinical trials in Type-2 diabetes mellitus in United Kingdom (SC) (NCT03550378)
  • 23 Jun 2018 Efficacy and adverse events data from a phase IIa trial in Type-2 diabetes mellitus presented at the 78th Annual Scientific Sessions of the American Diabetes Association (ADA-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top